List view / Grid view


Filter the results



MSD’s Hepatitis C drug given green light for EU market

9 August 2016 | By MSD

Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with…